- Key Facts
- Board of Governors
- Board of Directors
- Departments and Offices
- Policies and Strategies
- Annual Meetings
- Independent Evaluation
- Public Sector (Sovereign) Financing
- Private Sector (Nonsovereign) Financing
- Funds and Resources
- Asian Development Fund
- ASEAN Infrastructure Fund
- Investor Information[日本語]
- Business Opportunities
- Consulting Services
- ADB-Japan Scholarship Program
- News & Events
- Data & Research
- Industry and Trade
- Information and Communication Technology
- Public Sector Management
- Social Protection
- Capacity Development
- Climate Change
- Environmental Sustainability
- Gender and Development
- Poverty Reduction
- Private Sector Development
- Regional Cooperation and Integration
- Social Development
- Urban Development
- Brunei Darussalam-Indonesia-Malaysia-Philippines East ASEAN Growth Area (BIMP-EAGA)
- Central Asia Regional Economic Cooperation (CAREC)
- Greater Mekong Subregion (GMS)
- Indonesia-Malaysia-Thailand Growth Triangle (IMT-GT)
- South Asia Subregional Economic Cooperation (SASEC)
- European Representative Office
- Japanese Representative Office [日本語]
- North American Representative Office
- Pacific Liaison and Coordination Office
- Pacific Subregional Office
Countries with Operations
- China, People's Republic of [中文]
- Cook Islands
- Indonesia [Bahasa Indonesia]
- Kyrgyz Republic
- Lao PDR
- Marshall Islands
- Micronesia, Federated States of
- Papua New Guinea
Actions Agreed to Combat Drug Resistant Malaria
East Asia Summit and Pacific countries, international organizations, and experts have made 12 high-level recommendations to combat antimalarial drug resistance and accelerate progress towards the elimination of malaria in the region.
The recommendations were developed by the Asia Pacific Leaders Malaria Alliance’s (APLMA) Access to Quality Medicines and Other Technologies Taskforce, led by Australia and India, and co-chaired by their Secretaries of Health, Jane Halton and Lov Verma, and hosted by the Western Pacific Regional Office of the World Health Organization (WHO).
The taskforce recognized the efforts and resources already committed by countries, donors, and partners to the fight against malaria have achieved significant progress, and reduced the number of infections and deaths.
However, drug resistant malaria is putting these gains at risk.
The 12 recommendations propose actions to mitigate this risk by improving access to quality-assured anti malarials; stopping production of inappropriate therapies; improving diagnostic testing; improving coordination; and targeting hotspots in order to stop the spread of drug resistant malaria.
Ms. Halton said the region had a limited window of opportunity.
“There is potential for disaster if drug resistant malaria is not contained,” she said, emphasizing that it would not only result in more deaths and more human suffering, but subsequently lead to a loss of productivity in the region.
Mr. Verma highlighted the critical role of strengthening national drug regulatory authorities to improve access to quality drugs, mosquito nets, and diagnostic tests in both public and private sectors.
“Looking to the morbidity and mortality figures due to malaria, and the alarming rise of anti-malarial resistance, we need to accord top priority to this public health problem,” he said.
Dr. Shin Young-soo, WHO Regional Director for the Western Pacific, urged countries and partners to work together more closely on controlling drug resistance. “With artemisinin resistance, you are only as safe as your neighbor,” Dr. Shin pointed out. He continued, “the painful truth is that one large-scale stock-out of malaria medicines or insecticides and bed nets can reverse years of gains in a single season.”
APLMA is a leader-level initiative to promote regional collaboration against malaria disease in the region. APLMA is hosted and supported by the Asian Development Bank (ADB).
The taskforce’s recommendations will be finalized by August and then submitted to leaders.